Metastatic Pancreatic Adenocarcinoma
Conditions
Brief summary
Current standard of care for patients with metastatic Pancreatic Ductal AdenoCarcinoma (PDAC) is chemotherapy, preferential regimen being FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin). Due to more hematologic (neutropenia) and gastrointestinal toxicities, FOLFIRINOX is only administered in fit patients (age \< 75 years, ECOG Performance status 0-1, and bilirubin \< 1.5 ULN). However, elderly or frail patients represent more than half of patients with PDAC and are treated with gemcitabine monochemotherapy. Maintaining more than one drug (polychemotherapy) may improve survival and quality of life in this population. ALIX is a non-comparative randomized 2:1 phase II study. This study will assess the efficacy and safety of the polychemotherapy with XELOXIRI-3 versus gemcitabine as first-line chemotherapy in elderly or frail patients with locally advanced or metastatic PDAC.
Interventions
DRUGXELOXIRI-3
chemotherapy with XELOXIRI-3 regimen
DRUGGemcitabine
chemotherapy with Gemcitabine regimen
Sponsors
Centre Hospitalier Universitaire de Besancon
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Main Inclusion Criteria : * Histologically proven pancreatic ductal adenocarcinoma * Locally Advanced or metastatic disease * Measurable disease according to RECIST v1.1 criteria * Age ≥ 75 years; OR age between 65 and 75 years AND with at least one frailty contraindication to the administration of chemotherapy with FOLFIRINOX: * Eastern Cooperative Oncology Group Performance status (ECOG-PS) 2 * Total serum bilirubin \> 1.5 ULN (biliary drainage allowed) * Clinico-biological frailty criteria: * weight loss \> 10% in 6 months or \> 5% in 1 month * or body mass index (BMI) ≤ 21 * or serum albumin \< 30 g/L * or ADL (Activities of Daily Living) score \< 6 * Eligible for gemcitabine as first-line chemotherapy * Registration in a national health care system * Written informed consent obtained from the patient prior to performing any protocol-related procedures Main
Exclusion criteria
* Age \< 65 years * Localized non-metastatic cancer * ECOG-PS 3-4 * Previous treatment For advanced stage (locally advanced or metastatic): chemotherapy, radiochemotherapy; For localized stage: FOLFIRINOX chemotherapy (neoadjuvant or adjuvant); adjuvant chemotherapy with gemcitabine before relapse is permitted (provide it has been administered more than 6 months before) * Uncontrolled intercurrent cardiovascular disease * Known or suspected allergy or hypersensitivity to any of the study drugs (capecitabine, oxaliplatin, irinotecan, gemcitabine) * Bowel obstruction or sub-obstruction or impossible oral treatment * Prior peripheral neuropathy of grade ≥ 2 * Known complete dihydropyrimidine dehydrogenase (DPD) or UDP-glycosyltransferase 1 polypeptide A1 (UGT1A1) deficiency * Inadequate hematological, hepatic, and renal functions * Psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs (Adverse Events) or compromise the ability of the patient to give written informed consent * Tutelage or guardianship * Diagnosis of any second malignancy within the last 2 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri * Current participation in another clinical trial using therapeutic experimental agents
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 6 months Progression-Free Survival (PFS) rate | 6 months after the date of initiation of treatment (1st day of 1st cycle of chemotherapy) |
Countries
France
Outcome results
None listed